JK07
Asset
Neuregulin fusion protein selectively activates ERBB4 while blocking ERBB3, promoting cardiac repair and function.
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- Not known
- 2
- Indications
- 4
- Trials
- 1
- Developer
Trial NCT06369298 is still running. Trial NCT06369298 updated in its registry on May 22, 2026. clinicaltrials.gov
Indications
2Heart failure with reduced ejection fraction
Phase 2, Active not recruiting, NCT06369298, clinicaltrials.gov, Oct 31, 2026
Heart failure with preserved ejection fraction
Phase 2, Active not recruiting, NCT06369298, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials4
- Competitors3
Every asset’s record: target, stage, trials and the evidence behind it.